- Home
- PHGE vs MTNB Comparison
PHGE vs MTNB Comparison
Compare PHGE & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- MTNB
- Stock Information
- Founded
- PHGE 2015
- MTNB 2013
- Country
- PHGE Israel
- MTNB United States
- Employees
- PHGE N/A
- MTNB N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- MTNB Health Care
- Exchange
- PHGE Nasdaq
- MTNB Nasdaq
- Market Cap
- PHGE 12.6M
- MTNB 10.8M
- IPO Year
- PHGE N/A
- MTNB N/A
- Fundamental
- Price
- PHGE $0.55
- MTNB $1.88
- Analyst Decision
- PHGE Strong Buy
- MTNB Hold
- Analyst Count
- PHGE 1
- MTNB 1
- Target Price
- PHGE $15.00
- MTNB N/A
- AVG Volume (30 Days)
- PHGE 292.1K
- MTNB 55.7K
- Earning Date
- PHGE 11-13-2025
- MTNB 11-12-2025
- Dividend Yield
- PHGE N/A
- MTNB N/A
- EPS Growth
- PHGE N/A
- MTNB N/A
- EPS
- PHGE N/A
- MTNB N/A
- Revenue
- PHGE N/A
- MTNB N/A
- Revenue This Year
- PHGE N/A
- MTNB N/A
- Revenue Next Year
- PHGE N/A
- MTNB N/A
- P/E Ratio
- PHGE N/A
- MTNB N/A
- Revenue Growth
- PHGE N/A
- MTNB N/A
- 52 Week Low
- PHGE $0.34
- MTNB $0.47
- 52 Week High
- PHGE $1.16
- MTNB $4.25
- Technical
- Relative Strength Index (RSI)
- PHGE 56.74
- MTNB 55.11
- Support Level
- PHGE $0.50
- MTNB $1.83
- Resistance Level
- PHGE $0.54
- MTNB $1.97
- Average True Range (ATR)
- PHGE 0.03
- MTNB 0.13
- MACD
- PHGE 0.00
- MTNB -0.01
- Stochastic Oscillator
- PHGE 71.42
- MTNB 50.88
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.